BIOMAT Database Logo BIOMAT Database Logo

Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate. 2013

Mariko Kitahama, and Ayako Nakajima, and Eisuke Inoue, and Atsuo Taniguchi, and Shigeki Momohara, and Hisashi Yamanaka
Institute of Rheumatology, Tokyo Women's Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan. truthcld@hotmail.com

OBJECTIVE We aimed to assess the efficacy of tacrolimus (TAC) as an add-on therapy in patients with rheumatoid arthritis (RA) who were previously treated with methotrexate (MTX) but not with biologics. METHODS The study group (MTX + TAC group) consisted of 157 patients (selected from among the patients in the Institute of Rheumatology, Rheumatoid Arthritis [IORRA] RA cohort from April 2005 to October 2009) who received add-on therapy with TAC in addition to MTX, but without biologics. A propensity score (PS) for the use of TAC was derived, and 471 PS-matched patients who received MTX alone or MTX with other non-biologic disease-modifying antirheumatic drugs (except for TAC), but not with biologics, were selected and served as the control group. Changes in disease activity in the two groups during three consecutive IORRA phases were analyzed by adjusting for confounding factors. RESULTS The median 28-joint disease activity score (DAS28) decreased from 4.58 to 3.70 in the MTX + TAC group and from 4.12 to 3.61 in the control group. After adjusting for confounding factors, the decrease in the DAS28 score in the MTX + TAC group was significantly larger (by 0.273 points) than that in the control group (P < 0.05). CONCLUSIONS This study demonstrated the efficacy of add-on therapy with TAC to MTX in patients with RA in daily practice.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

Mariko Kitahama, and Ayako Nakajima, and Eisuke Inoue, and Atsuo Taniguchi, and Shigeki Momohara, and Hisashi Yamanaka
Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate.
June 2019, International journal of rheumatic diseases,
Mariko Kitahama, and Ayako Nakajima, and Eisuke Inoue, and Atsuo Taniguchi, and Shigeki Momohara, and Hisashi Yamanaka
Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate.
July 2016, The Korean journal of internal medicine,
Mariko Kitahama, and Ayako Nakajima, and Eisuke Inoue, and Atsuo Taniguchi, and Shigeki Momohara, and Hisashi Yamanaka
Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate.
June 2016, Rheumatology and therapy,
Mariko Kitahama, and Ayako Nakajima, and Eisuke Inoue, and Atsuo Taniguchi, and Shigeki Momohara, and Hisashi Yamanaka
Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study.
January 2008, Modern rheumatology,
Mariko Kitahama, and Ayako Nakajima, and Eisuke Inoue, and Atsuo Taniguchi, and Shigeki Momohara, and Hisashi Yamanaka
Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders.
September 2015, Modern rheumatology,
Mariko Kitahama, and Ayako Nakajima, and Eisuke Inoue, and Atsuo Taniguchi, and Shigeki Momohara, and Hisashi Yamanaka
[Treatment with methotrexate in patients with rheumatoid arthritis].
December 1987, Nederlands tijdschrift voor geneeskunde,
Mariko Kitahama, and Ayako Nakajima, and Eisuke Inoue, and Atsuo Taniguchi, and Shigeki Momohara, and Hisashi Yamanaka
The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
January 2017, Modern rheumatology,
Mariko Kitahama, and Ayako Nakajima, and Eisuke Inoue, and Atsuo Taniguchi, and Shigeki Momohara, and Hisashi Yamanaka
Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis.
January 2010, Open access rheumatology : research and reviews,
Mariko Kitahama, and Ayako Nakajima, and Eisuke Inoue, and Atsuo Taniguchi, and Shigeki Momohara, and Hisashi Yamanaka
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
September 2016, Arthritis research & therapy,
Mariko Kitahama, and Ayako Nakajima, and Eisuke Inoue, and Atsuo Taniguchi, and Shigeki Momohara, and Hisashi Yamanaka
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.
November 2006, Annals of the rheumatic diseases,
Copied contents to your clipboard!